Mounjaro (Tirzepatide) is an injectable prescription medication used alongside diet and exercise to improve blood sugar levels in adults with type 2 diabetes mellitus.
Why Choose Mounjaro (Tirzepatide)?
Mounjaro (Tirzepatide) is a treatment option for adults with type 2 diabetes when diet and exercise alone do not control blood sugar levels adequately. It is the first and only GIP and GLP-1 receptor agonist medication that activates natural incretin hormones to regulate blood sugar levels. In clinical trials, it has been shown to deliver superior A1C reductions, and for eligible patients, it can also support weight loss efforts.
How to Use Mounjaro (Tirzepatide)?
Mounjaro is an injectable medication prescribed for adults with type 2 diabetes to help manage their blood sugar levels. To ensure safe and effective use, patients should:
Read the Medication Guide and Instructions For Use provided by their pharmacist before starting and each time they get a refill.
Administer Mounjaro as a subcutaneous injection once a week, using the single-dose pen which comes in various dosages: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL.
Start with a 2.5 mg dose once a week for the first four weeks, then potentially increase to 5 mg per week depending on the doctor’s advice. Dosage adjustments should be made in 2.5-mg increments after at least 4 weeks at the current dose, with a maximum dose of 15 mg weekly.
Check the product visually for particles or discoloration before use.
Follow any specific preparation and usage instructions provided by healthcare professionals.
Mounjaro should be used in conjunction with a proper diet and exercise regimen.
It is not suitable for individuals with type 1 diabetes or those who have had pancreatitis.
Important and Safety Information about Mounjaro (Tirzepatide)
Important safety information includes warnings about potential thyroid tumors, including thyroid cancer, so patients should monitor for symptoms like neck lumps, hoarseness, or trouble swallowing and avoid Mounjaro if they have personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Fact Table
Fact Category
Fact Details
Brand Name
Mounjaro
Generic Name
Tirzepatide
Medication Class
Antidiabetic medication
Indications
Treatment of type 2 diabetes and for weight loss in adults.
Administration
Route Subcutaneous injection (under the skin).
FDA Approval
Approved by the Food and Drug Administration (FDA) in May 2022.
Mechanism of Action
Acts as a dual receptor agonist on glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to lower blood glucose levels.
Dosage Forms
Available in multiple strengths including 2.5mg, 5mg, 7mg, 10mg, 12.5mg, and 15mg.
Dosage Frequency
Once weekly injection.
Usage
Intended to be used as an adjunct to diet and exercise.
Special Considerations
The dosage involves titration to the appropriate dose based on the patient’s needs and response to treatment.
Common Side Effects
Like all medications, Mounjaro (Tirzepatide) can cause side effects, although not everybody gets them. Understanding these side effects can help you use this medication safely and effectively.
Nausea
Diarrhea
Decreased appetite
Vomiting
Constipation
Indigestion
Abdominal pain
If you experience any side effects, discuss them with your healthcare provider. They can offer advice and may adjust your treatment if necessary. Report any severe or unexpected side effects immediately.
